Peer-reviewedCC BYClinical Case Reports
Erythroderma Following Fluphenazine Decanoate Injection: A Rare Adverse Drug Reaction in a Resource‐Limited Setting
- 1Keren Zonal Referral Hospital Keren Eritrea
- 2Afabet Hospital Afabet Eritrea
- 3Mendefera Zonal Referral Hospital Mendefera Eritrea
Abstract
Fluphenazine may rarely cause severe erythroderma. Early recognition, prompt discontinuation of the offending drug, and supportive management are essential to prevent serious complications, particularly in resource‐limited settings.
Related
- Delayed Histiocytic Foreign Body Reaction and Granuloma Formation Following Argiform Injection for Soft Tissue Augmentation Mimicking a Lipomatous Tumor on Histopathology: A Case Report.
- Recurrent Delayed Inflammatory Reaction After Dermal Filler Injection Treated With Intralesional 5-fluorouracil, Triamcinolone, and Hyaluronidase.
- Bulging of the Masseter Muscle Following Botulinum Neurotoxin Type A Injection
- Adult-onset Still Disease Flare 5 Days Following Poly-l-lactic Acid Injection: A Cautionary Tale for Aesthetic Practice
- Early Radiographic Improvement of Pain-Induced Sciatic Scoliosis Following Transforaminal Epidural Steroid Injection in Lumbar Disc Herniation: A Prospective Cohort Study
BibTeX
@article{riesehaymanot2026erythroderma,
title = {{Erythroderma Following Fluphenazine Decanoate Injection: A Rare Adverse Drug Reaction in a Resource‐Limited Setting}},
author = {Filmon Tesfay Riesehaymanot and Lidya Musie Tekeste and Nahom Daniel Berhe},
journal = {Clinical Case Reports},
year = {2026},
month = nov,
doi = {10.1002/ccr3.73938},
url = {https://doi.org/10.1002/ccr3.73938},
note = {CC BY},
}
RIS
TY - JOUR
TI - Erythroderma Following Fluphenazine Decanoate Injection: A Rare Adverse Drug Reaction in a Resource‐Limited Setting
AU - Filmon Tesfay Riesehaymanot
AU - Lidya Musie Tekeste
AU - Nahom Daniel Berhe
PY - 2026
DA - 2026/11/16
JO - Clinical Case Reports
DO - 10.1002/ccr3.73938
UR - https://doi.org/10.1002/ccr3.73938
AB - Fluphenazine may rarely cause severe erythroderma. Early recognition, prompt discontinuation of the offending drug, and supportive management are essential to prevent serious complications, particularly in resource‐limited settings.
SN - 2050-0904
ER -